Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer-Reference-Cited by-同舟云学术

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer

Published:2018-02 Issue:2 Volume:267 Page:364-369
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Tatarian Talar,Jiang Wei,Leiby Benjamin E.,Grigoli Amanda,Jimbo Masaya,Dabbish Nooreen,Neoptolemos John P.,Greenhalf William,Costello Eithne,Ghaneh Paula,Halloran Christopher,Palmer Daniel,Buchler Markus,Yeo Charles J.,Winter Jordan M.,Brody Jonathan R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference23 articles.

1. Pancreatic cancer;Hidalgo;N Engl J Med,2010

2. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer;Neoptolemos;N Engl J Med,2004

3. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007

4. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;Oettle;JAMA,2013

5. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma;Neoptolemos;J Clin Oncol,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of the potential of African medicinal plants and their derived products against pancreatic cancer;Advances in Botanical Research;2024

2. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs;Drug Resistance Updates;2023-11

3. Survival and Late Morbidity after Resection of Pancreatic Cancer;The Pancreas;2023-08-04

4. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma;Annals of Surgery;2023-05-25

5. Relationship between HuR and tumor drug resistance;Clinical and Translational Oncology;2023-03-22